EVKEEZA 150 MG
EVINACUMAB : 150 MG · DIN 02541769 · ULTRAGENYX PHARMACEUTICAL INC
Health Canada status: MARKETED
What is EVKEEZA?
EVKEEZA 150 MG contains EVINACUMAB : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02541769, held by ULTRAGENYX PHARMACEUTICAL INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 21-Nov-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EVKEEZA used for?
Adjunct to diet and other LDL-C lowering therapies for the treatment of adult and pediatric patients 6 months and older with homozygous familial hypercholesterolemia (HoFH).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02541769 |
|---|---|
| Brand name | EVKEEZA |
| Generic / active ingredient | EVINACUMAB : 150 MG |
| Manufacturer | ULTRAGENYX PHARMACEUTICAL INC |
| Strength | 150 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | C10AX17 EVINACUMAB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Nov-2023 |
How is it administered?
15 mg/kg administered by intravenous (IV) infusion over 60 minutes every 4 weeks. Administered by a health professional only. Rate may be slowed or interrupted if adverse reactions occur.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 2°C to 8°C. If refrigerated, allow to come to room temperature (up to 25°C) prior to administration. Administer immediately once prepared.
How is it supplied?
345 mg/2.3 mL (150 mg/mL) and 1,200 mg/8 mL (150 mg/mL) single-use vials.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation.
Warnings and precautions
Hypersensitivity reactions including anaphylaxis and infusion reactions reported. Potential for fetal harm; determine pregnancy status before initiation.
Who else supplies EVINACUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. EVINACUMAB appears in 2 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.